arrow
D

Derek J. Hausenloy

national heart centre singapore
H指数:106
被引数:4.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fifth Universal Definition of Myocardial Infarction (2026)

第五版心肌梗死通用定义(2026)

2026-08-280
PRE
The global cardiovascular-kidney-liver-metabolic burden from 1990 to 2023

1990年至2023年全球心血管-肾脏-肝脏-代谢负担

2026-08-010
OAAI
Treatment of OSA using mandibular advancement versus CPAP in improving cardiovascular health

使用下颌前移与CPAP治疗OSA对改善心血管健康的影响

2026-04-190
OAAI
Mitochondrial Dynamic Proteins MiD49 and MiD51 as Novel Targets of Cardioprotection

线粒体动态蛋白MiD49和MiD51作为新型心脏保护靶点

Cells
IF5.2
2026-03-200
OA
Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study

Senanayake, S.; Lee, A.S.Y.; Graves, N.; Win, P.P.S.; Lee, A.; Lau, Y.H.; Hausenloy, D.J.; Yeo, K.-K.; Chan, M.Y.-Y.; Wong, R.C.C.; 等. 新加坡射血分数降低心力衰竭患者指南推荐药物治疗中的治疗差距:一项多中心回顾性队列研究的结果. BMJ Open 2026, 16, e104127. [Google Scholar] [CrossRef]

2026-03-121
PRE
Correction: IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): a small animal acute myocardial infarction randomized-controlled multicenter study on the effect of ischemic preconditioning

更正:改善心血管保护疗法预临床评估(IMPACT):一项关于缺血预处理对急性心肌梗死影响的小动物随机对照多中心研究

2025-11-100
OAAI
Risk of new-onset heart failure and heart failure exacerbations following COVID-19, influenza, or respiratory syncytial virus hospitalization

COVID-19、流感或呼吸道合胞病毒住院治疗后新发心力衰竭和心力衰竭恶化的风险

2025-11-011
PRE
The Asia Pacific Cardiovascular Research (ASPIRE) Network Facilitating and Advancing Regional Cardiovascular Clinical Trials
2025-10-010
OAAI
Extracellular RNA Drives TNF-α/TNF-Receptor-1 mediated cardiac ischemia/reperfusion injury: Mechanistic insights and therapeutic potential of RNase1

细胞外RNA驱动TNF-α/TNF受体-1介导的心脏缺血/再灌注损伤:RNase1的作用机制与治疗潜力

2025-09-120
OAAI
Cost analysis of exercise cardiac magnetic resonance imaging in suspected dilated cardiomyopathy—a single-center experience

疑似扩张型心肌病运动心脏磁共振成像的成本分析——一项单中心经验

2025-06-100
OAAI
Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function

缺血性心脏病和心力衰竭中的线粒体靶点及其更高效临床转化的潜力。欧洲心脏病学会(ESC)心脏细胞生物学工作组与ESC心肌功能工作组的科学声明

2025-05-040
OAAI
Guideline-directed Medical Therapy in Nonagenarians and Centenarians (≥ 90 Years Old) After First-onset Myocardial Infarction---A National Registry Study

基于指南的医疗治疗在90岁及以上首次心肌梗死患者中的应用---一项全国注册研究

2025-01-310
PRE